ORLANDO, Fla. (Reuters) - A drug developed by Portola Pharmaceuticals to rapidly reverse the effect of new blood thinning agents in cases of major bleeding or other emergencies proved highly effective ...

The market for oral anticoagulants has advanced significantly since warfarin was essentially the lone option. Still, in some cases, the use of improved direct oral anticoagulants (DOACs) can provoke ...

Andexanet alfa (Andexxa; AstraZeneca), compared with usual care, improves hemostasis in patients who have an intracranial bleed while taking a factor Xa inhibitor, according to top-line results of ...

AstraZeneca announced that Ondexxya (andexanet alfa) has been approved in Japan for patients treated with the Factor Xa (FXa) inhibitors apixaban, rivaroxaban or edoxaban, when reversal of ...

Agents that reverse the effect of direct oral anticoagulants (DOACs) are highly effective in patients with severe bleeding, but mortality rates remain high despite their use, a meta-analysis shows.

PHOENIX, AZ—Much like in the setting of acute ischemic stroke, shorter times to treatment are associated with better outcomes in patients with anticoagulation-associated intracerebral hemorrhage (ICH) ...

Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk between the two ...

Switching from Eliquis (apixaban) to rivaroxaban in Non-Valvular Atrial Fibrillation (NVAF) patients was associated with a higher risk of stroke/systemic embolism (S/SE) and major bleeding (MB) than ...

Please provide your email address to receive an email when new articles are posted on . Apixaban was not superior to standard of care antithrombotic treatment for preventing thrombotic or bleeding ...